The application for domestic manufacturing and marketing is based on a doctor-based interim analysis of 13 subjects (corresponding to phase II) with the oncolytic herpes simplex virus vector G47Δwhich showed a 92.3 % survival rate.
Nikkei Biotech news release, February 14, 2019
Daiichi Sankyo to apply for approval of gene therapy for cancer treatment